Forum Posts

Damon Salvatore
Jun 29, 2022
In Education Forum
Over time, many pharma companies have begun incorporating augmented reality (AR) and virtual reality (VR) features, in order to offer an experiential and interactive dimension to their educational / marketing content Roots Analysis has done a detailed study on “AR / VR based Healthcare Digital Marketing Service Providers Market, 2020-2030” covering key aspects of the industry’s evolution and identifying potential future growth opportunities. Over time, various pharma players have taken advantage of these immersive technologies for education, training as well as marketing, purposes. These AR and VR technology has been demonstrated to be capable of driving better customer engagement, and generating useful insights based on their expectations and purchase behaviors. Given the increasing demand for AR and VR in healthcare and pharma marketing, several stakeholders are expected to forge alliances with AR / VR service providers in the foreseen future. Owing to the rising interest of big pharma players in this domain, we expect an escalated industry-wide adoption of such technologies. The report features an extensive study of the current market landscape and future opportunities associated with the AR / VR based digital marketing industry in the healthcare domain. Amongst other elements, the report features: § A review of the current market landscape of companies offering AR / VR based digital marketing services. § An insightful representation, highlighting the competitiveness analysis of digital marketing companies. § Elaborate profiles of prominent digital marketing companies, featuring a brief overview of the company, its financial information (if available), recent developments and an informed future outlook. § An analysis highlighting the potential strategic partners segregated on the basis of their likelihood of entering into collaboration with digital marketing companies. § An analysis of various AR / VR based digital marketing initiatives of big pharma players (shortlisted based on extent of activity in this domain), based on multiple parameters. § A case study on recent use cases, wherein various digital marketing strategies have been adopted by pharmaceutical / healthcare players. § A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below): § Type of Technology AR Based Services MR Based Services VR Based Services § Type of product Hardware Software § End-User Large Companies Small and Mid-sized Companies § Key Geographical Regions North America Europe Asia-Pacific Rest of the World Key companies covered in the report § ARWorks § CG Life § CubeZoo § Impact XM § INVIVO Communications § Mirum § Pixacore § Random42 § Quast Media § Tipping Point Media § vStream For more information, please visit https://www.rootsanalysis.com/reports/view_document/healthcare-digital-marketing/323.html Other recent offerings You may also be interested in the following titles: 1. Global Collaborative Robots (Cobots) Market, 2020-2030 2. Digital Health Marketv: Focus on Digital Therapeutics (2nd Edition), 2020-2030 3. Digital Twin Market: Global Opportunity and Trend Analysis, 2020-2035 4. Gene Therapy Market : Industry Trends and Global Forecasts (5th Edition), 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
0
0
1
Damon Salvatore
Jun 28, 2022
In Education Forum
The recent approval of Aduhelm™, an amyloid beta-directed antibody has led to players seeking approval for similar therapies; various interventions are being evaluated for the treatment / management of the inherently complex neurodegenerative disease Roots Analysis has announced the addition of “Alzheimer's Disease Market (2nd Edition), 2021-2031” report to its list of offerings. Limited treatment options and unmet needs are the key drivers of research activity in this domain. Several industry and non-industry players are presently engaged in developing various types of disease modifying interventions and drug / therapy candidates that offer symptomatic relief. Moreover, multiple venture capital firms and other strategic investors have been supporting the research related initiatives of various start-ups. Driven by a rich development pipeline and the efforts of various stakeholders, the market is anticipated to grow at a significant pace in the coming future. To order this 150+ page report, which features 90+ figures, please visit https://www.rootsanalysis.com/reports/view_document/alzheimers-disease-market/247.html Key Market Insights More than 240 drug candidates for the treatment of Alzheimer’s disease and associated symptoms are currently being investigated Over 90% of the therapies are being evaluated across preclinical and clinical stages, either as monotherapies or in combination with other products. Majority of the drugs (60%) are designed for oral administration. 190,000+ patients have been enrolled in over 2,000 clinical trials, worldwide Clinical research activity, in terms of number of trials registered, is reported to have increased at a CAGR of around 40% in the last five years. Of the total number of trials, close to 65% have already been completed, while 25% are active and still recruiting patients. Close to 20,000 articles focused on Alzheimer’s disease and related symptoms have been published since 2017 Several industry and non-industry players engaged in this domain are undertaking numerous initiatives to identify and develop novel therapies for this neurodegenerative condition. Majority (81%) of the articles published by authors affiliated to deemed universities are focused on studying the disease pathology. Several partnerships were established in this domain, during the period 2017-2021 Maximum number of partnerships were observed to be inked in 2018, indicating a recent rise in the interest of various players engaged in this domain. Majority of the deals were reported to be research and development agreements, representing over 34% of the total number of instances. Over USD 4 billion has been invested by both private and public investors, since 2013 Of the total, close to USD 2 billion was raised through venture capital financing, representing over 40% of the overall share. On the other hand, 25 instances of debt financing were also reported, wherein players collectively received more than USD 300 million. North America and Europe anticipated to capture over 90% of market share by 2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the growing demand for various therapeutic modalities. It is worth mentioning that disease modifying treatment market is projected to hold over 57% of the total market share by 2030. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/view_document/alzheimers-disease-market/247.html Key Questions Answered § Who are the leading industry players involved in the Alzheimer’s disease industry? § Which geographies are the most active in conducting clinical trials on therapies for Alzheimer’s disease? § Which are the leading funding organizations providing grants in the Alzheimer’s disease industry? § Which partnership models are commonly adopted by industry stakeholders in the Alzheimer’s disease industry? § How is the current and future market opportunity, related to Alzheimer’s disease, likely to be distributed across key market segments? The financial opportunity within the Alzheimer’s disease market size has been analyzed across the following segments: § Type of Treatment Symptomatic Treatment Disease Modifying Treatment § Type of Symptomatic Indications Dementia Insomnia Other Psychological Symptoms § Key Geographical Regions North America Europe Asia-Pacific and RoW’ The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the adoption of display library technologies. The report includes detailed transcripts of the discussions held with the following industry experts: § Kenneth Moch (President and Chief Executive Officer, Cognition Therapeutics) § Mathias Schmidt (Chief Executive Officer, ArmaGen) § Ram Bhatt (Chief Executive Officer, Chairman and Founder, ICB International) The research also includes detailed profiles of the companies (listed below) engaged in developing therapies for Alzheimer’s disease; each profile features an overview of the developer, details related to its financials (if available), product portfolio, recent developments, and an informed future outlook. § AbbVie § AC Immune § Actinogen Medical § Allergan (now part of AbbVie) § Biogen § Eisai § Eli Lilly and Company § GlaxoSmithKline § Grifols § Neurim Pharmaceuticals § Novartis § Novo Nordisk § Roche § Takeda Pharmaceutical For additional details, please visit https://www.rootsanalysis.com/reports/view_document/alzheimers-disease-market/247.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Squamous Non-Small Cell Lung Cancer Market, 2021-2031 2. Novel T-Cell Immunotherapies Market, 2021-2030 3. HER2 Targeting Therapies Market, 2021-2030 4. Glycated Haemoglobin HbA1c Testing Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
0
0
1
Damon Salvatore
Jun 27, 2022
In Education Forum
The exact cause of this rare disorder, which affects 5-17 in 100,000 people, is unknown; however, a complex interplay between different risk factors, including age, genetics and environment, is likely to contribute to the onset of this rare tauopathy London Roots Analysis has announced the addition of “Progressive Supranuclear Palsy Therapies Market, 2021-2030” report to its list of offerings. Presently, there is no cure for PSP and the effectiveness of prescribed generic medications and non-drug therapies to improve the quality of life in patients, is limited. The high unmet patient need and rising caregiver burden has inspired several players to focus their efforts on the development of therapies to control the progression of PSP or manage its symptoms. Consequently, multiple orphan designated drugs, currently in phase II of development, are anticipated to enter the market in the next 3-6 years. To order this 100+ page report, which features 70+ figures, please visit https://www.rootsanalysis.com/reports/progressive-supranuclear-palsy-market.html Key Market Insights Currently, over 20 drugs are being developed across preclinical and clinical stages Majority (50%) of the drug candidates are being evaluated in phase I clinical studies to ease the complexities associated with PSP. Further, owing to their ability to cross the blood-brain barrier, small molecule drugs represent ~70% of the PSP pipeline; this is followed by anti-tau antibodies and antisense oligonucleotides. Since majority of the drugs are small molecules, oral route is the most preferred route.The players that are engaged in the development of drug products / therapies for progressive supranuclear palsy Close to 20 industry and non-industry players are engaged in the development of drugs for PSP Majority of the industry players (59%) are small firms / start-ups (with less than 50 employees). North America is the current hub, where close to 60% players are based. Further, a few non-industry players, including Washington University and Scripps Research, are leading the development of several early- stage PSP programs. More than 100 trials, related to PSP, were registered in the last two decades It is worth mentioning that around 52% of the trials were / are being conducted in Europe and Asia-Pacific region, however, more than 60% of the patients are enrolled in clinical trials conducted in North America. Further, most of the studies are focused on investigating tau targeted radiopharmaceuticals for PSP. Around 80 eminent scientists, clinicians and industry veterans, with specialization in neurobiology, emerged as key opinion leaders (KOLs), in this domain Nearly 50% of these KOLs are associated with organizations based in Europe, followed by North America. Multiple individuals from University of California, San Francisco and Toulouse Hospital and University Center are involved in clinical studies for PSP drugs. Further, 76% of these KOLs have doctoral degrees, namely MD and PhD. Grants worth over USD 300 million have been awarded to support PSP research, since 2010 Till July 2021, over 700 grants have been disbursed to various companies / organizations working in this domain. National Institute on Ageing and National Institute of Neurological Disorders and Stroke emerged as the most active funding institutes, contributing to over 90% of the total grant amount. In the last two decades, ~2400 articles on PSP, have been published in neuroscience journals Over the years, there has been a gradual rise in the number of publications related to PSP; nearly 50% of the articles have been published since 2017. With over 150 articles, Parkinsonism & Related Disorders and Journal of Movement Disorders emerged as the key journals. Several partnerships were established by stakeholders in this domain, since 2015 More than 75% of the reported deals were established since 2018, with the maximum activity being reported in 2019. Majority of the instances captured in the report were research and development agreements (33%), followed by licensing agreements (25%). By 2030, curative therapies, targeting molecular mechanism underlying PSP, are likely to represent over 90% of the market share (in terms of sales revenue) Growth in this domain is anticipated to be driven by the lack of competition from generics and consequently steering adoption of high-priced curative treatments. It is worth noting that US is likely to capture the highest market share (over 65%). Further, the market in Europe is anticipated to grow at a CAGR of ~25%, in the period 2024-2030. To request a sample copy / brochure of this report, please visit : https://www.rootsanalysis.com/reports/progressive-supranuclear-palsy-market/request-sample.html Key Questions Answered § What are the prevalent R&D trends related to PSP? § What are the key challenges faced by stakeholders developing PSP therapies? § Which are the principal therapies being developed for PSP? § Who are the leading industry and non-industry players in the PSP therapies market? § Which are the key geographies where research on PSP is being conducted? § Which are the leading administering institute centers supporting the research related to PSP therapies? § Who are the key opinion leaders / experts that have contributed to the domain of PSP therapies? § What kind of partnership models are commonly adopted by stakeholders engaged in this industry? § What are the factors that are likely to influence the evolution of PSP therapies market? § How is the current and future market opportunity likely to be distributed across key market segments? The USD 492 million (by 2030) financial opportunity within the PSP market has been analyzed across the following segments: § Phase II Drugs § AZP2006 § RT001 § BRAVYL § Emeramide § NORTHERA § Type of Treatment § Curative § Symptomatic / Palliative § Key Geographical Regions § North America (US) § Europe (France, Germany, Italy, Spain, UK) The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts: § Daniel Brennan (Business and Operations Advisor, NeuroTau) § Fabrizio Stocchi (Director of the Parkinson’s Disease and Movement Disorders Research Center, IRCCS San Raffaele) The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, as well as an informed future outlook. § Alzprotect § Retrotope § Woolsey Pharmaceuticals § EmeraMed § Lundbeck § NeuroTau You may also be interested in the following titles: 1. Brain Concussion Market, 2021-2031 2. Hunter Syndrome: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 3. Pediatric Brain Tumors: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 4. Neurotrophic Keratitis: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 5. Neuromyelitis Optica Spectrum Disorder (2nd Edition): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2031 6. Medical Device Contract Manufacturing Market (CMO), 2019-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
0
0
1
Damon Salvatore
Jun 17, 2022
In Education Forum
Owing to the incessant increase in disease incidence rates and the lack of effective treatment options, the pharmaceutical industry is unable to cater to the growing demands across various therapeutic areas. Interestingly, recent developments in pharmacology and biotechnology have been able to drive significant advances and innovation in understanding the root causes of various diseases; this has further aided in the discovery and development of more targeted treatment strategies. It is worth noting that such advances in the healthcare industry have made the pharmaceutical development and manufacturing processes even more complex. Outsourcing has emerged as a prominent trend, especially for manufacturing and fill / finish operations, to meet the increasingly complex demands of the industry. The pharmaceutical contract manufacturing market is characterized by the presence of both niche, specialty companies, focused on early-stage development and production (preclinical and / or clinical scales), and one-stop-shop contract manufacturing organizations (CMOs) possessing an extensive range of capabilities, catering to product development, commercialization and various other requirements of their clients. For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/pharmaceutical-contract-manufacturing-market/191.html The complete development of a pharmaceutical product is a multifaceted process and selecting a suitable CMO for outsourcing different operations is one of the main challenges faced by pharmaceutical companies. Despite the cost benefits they offer and their extensive technical capabilities, there are several parameters that need to be considered while selecting a CMO partner. The selection of a wrong / improper CMO partner can prove to be disastrous in the long run, when issues such as delays and cost overruns, crop up. Some of the most important factors that need to be considered while selecting a contract manufacturing partner include size, financial stability, technical expertise, cost, operational flexibility, geographical location and work experience. You may also be interested in the following reports: 1. Peptide Therapeutics 2. Biopharmaceutical Excipient Manufacturing Market 3. Single-use Sensors for Bioprocessing Market 4. Oligonucleotide Synthesis Market, Modification and Purification Services Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
0
0
1
Damon Salvatore
Jun 16, 2022
In Education Forum
To order this detailed 200+ page report, please visit https://www.rootsanalysis.com/reports/next-generation-sequencing-kits-market.html Key Inclusions § A detailed assessment of the current market landscape of NGS library preparation kits, featuring information on the type of nucleotide sequenced (DNA and RNA), kit components (control total RNA / DNA, adapters, primers, enzyme mixes, buffers, RNA / DNA probes and others), quantity of sample required (less than 5 ng, 5 ng to 10 ng and more than 10 ng), turnaround time (less than 5 hours, 5 hours to 10 hours and more than 10 hours), storage temperature (deep freeze, cold and room temperature), type of sample used (purified RNA / DNA, plasma, serum, urine, cells, blood, saliva and others), kit shelf life (0.5 year and 1 year), type of sequencing (whole genome sequencing, targeted sequencing, transcriptome sequencing, RNA sequencing, ChIP sequencing, exome sequencing, bisulphite sequencing, methyl sequencing, amplicon sequencing, de novo sequencing, resequencing and shotgun sequencing) and type of sequencing platform used (Illumina, BGI, Ion Torrent, Fluidigm and Oxford Nanopore Technologies). In addition, the chapter features analysis related to NGS library preparation kit providers based on parameters, such as year of establishment, company size, location of headquarters and leading players (in terms of number of products). § A competitiveness analysis of NGS library preparation kits based on various relevant parameters, namely supplier power (based on the experience of the developer) and product competitiveness (based on parameters, including type of nucleotide sequenced, kit components, quantity of sample required, turnaround time, type of sample used, kit shelf life, type of sequencing and type of sequencing platform used). § Elaborate profiles of prominent players offering NGS library preparation kits, based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and an informed future outlook. § An in-depth analysis of the various patents that have been filed / granted related to NGS library preparation kits and reagents, from January 2020 to October 2021, taking into consideration parameters, such as publication year, geographical region, CPC symbols, patent focus areas, type of applicant and leading players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis. § A case study on the history and evolution of genome sequencing with details on first, second and third generation sequencing platforms. The chapter includes information on the NGS technologies that are available till date. Further, it presents information on the various NGS service providers (industry and non-industry players) that are engaged in providing whole genome, whole exome and targeted sequencing services. § The NGS market is anticipated to grow at a CAGR of 18%, till 2035, and the projected opportunity is likely to be distributed across different type of nucleotide sequenced, end user and key geographical regions The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: § Type of Nucleotide Sequenced DNA RNA § Type of End User Academic and Research Institutes Pharmaceutical and Biotechnology Companies Hospitals and Clinics Others § Key Geographical Regions North America Europe Asia Pacific Latin America Middle East and North Africa Rest of the World To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/next-generation-sequencing-kits-market.html Key Questions Answered § Who are the key players engaged in offering NGS library preparation kits? § What is the relative competitiveness of different NGS library preparation kits? § How is the intellectual property landscape for next generation sequencing kits likely to evolve in the foreseen future? § What are the factors that are likely to influence the evolution of this market? § How is the current and future market opportunity likely to be distributed across key segments? For more information please click on the following link: https://www.rootsanalysis.com/reports/next-generation-sequencing-kits-market.html Other Recent Offerings 1 At-Home Blood Collection and Micro Sampling Devices Market: Industry Trends and Global Forecasts, 2021-2030 2 Global Pharmaceutical Vials Market: Industry Trends and Global Forecasts, 2021-2030 3 Novel Drug Reconstitution Systems Market: Industry Trends and Global Forecasts, 2021-2030 4 Bioprocess Controllers and Automation Systems Market: Industry Trends and Global Forecasts, 2021-2030 5 Novel Ocular Drug Delivery Devices Market: Industry Trends and Global Forecasts, 2021-2030 6 Cell Therapy Packaging Products and Services Market: Industry Trends and Global Forecasts, 2021-2030 7 Solar Tracker Market: Global Opportunity and Trend Analysis, 2021-2031 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
0
0
1
Damon Salvatore
Jun 13, 2022
In Education Forum
Amidst the COVID-19 pandemic, there has been an evident surge in the demand for high quality cell therapies intended for research and therapeutic purposes, presenting lucrative opportunities for consumable providers having capabilities for raw material production London Roots Analysis has announced the addition of the “Cell Therapy Consumables Market” report to its list of offerings. Currently, more than 800 IND applications have been filed for cell therapies, while close to 10 cell-based / gene therapies are likely to receive approval in 2021 across the world. This has prompted several drug developers to rely on third-party service providers that claim to have the required skillset and technical infrastructure for the production of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents, in order to produce quality cellular therapies. To order this 230+ page report, which features 110+ figures and 120+ tables, please visit this https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.html Key Market Insights Presently, more than 60 players claim to provide cell therapy consumable products This segment of the industry is dominated by start-ups / small companies (2-50 employees) and mid-sized players (51-200 employees), which represent more than 70% of the total consumable providers. In addition, around 48% players were established before 2001, while about 25% were founded post 2010. Currently, media products capture the highest share (73%) of the cell therapy consumables Most of the cell therapy media are being developed for stem cell therapies (72%), followed by those intended for T-cell therapies (21%). It is worth noting that all cell therapy media are currently used for research purposes, followed by those employed for therapeutic purposes (16%). 85+ consumable facilities dedicated to cell therapies have been established worldwide North America has emerged as the consumable hub for cell therapies, featuring the presence of nearly 65% of the total consumable facilities; this is followed by Europe (21%). Other emerging regions include (in decreasing order of number of facilities) Japan, China, India and South Korea. Partnership activity in this domain has increased at a CAGR of over 39%, between 2016 and 2021 Acquisitions and product commercialization agreements emerged as the most popular types of partnership models adopted by industry stakeholders (19% each), followed by distribution agreements (16%) and manufacturing agreements (10%). Around 71% of the total expansion projects undertaken by stakeholders were initiated since 2018. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/cell-therapy-consumables-market/request-sample.html Key Questions Answered § Who are the key players engaged in offering consumables for cell therapies? § Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities? § Which are the most popular media components used for cell therapy consumables? § What kind of partnership models are most commonly adopted by stakeholders engaged in this industry? § How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies? § What are the key challenges associated with the production of cell therapy consumables? § What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process? § How is the current and future market opportunity likely to be distributed across key market segments? § What are the anticipated future trends related to consumables market for cell therapies? The financial opportunity within the cell therapy consumables market has been analyzed across the following segments: § Type of Consumable § Kits § Media § Reagents § Type of Cell Therapy § Dendritic Cell Therapy § NK Cell Therapy § Stem Cell Therapy § T-Cell Therapy The report includes profiles of key players (listed below) each profile features an overview of the company, details related to its financials (if available), product portfolios, recent developments and an informed future outlook. § Miltenyi Biotec § STEMCELL technologies § Bio-Techne § Irvine Scientific § Thermo Fisher Scientific § Sartorius § BD Biosciences § Lonza § CellGenix § Corning For additional details, please visit https://www.rootsanalysis.com/reports/cell-therapy-consumables-market.htmlor email sales@rootsanalysis.com You may also be interested in the following titles: 1. Biospecimen Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030 2. Pharmaceutical Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030 3. Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics (2nd Edition) About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
0
0
1

Damon Salvatore

More actions